- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375487
The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial
May 11, 2022 updated by: Universidade Nova de Lisboa
Functional constipation (FC) is a common condition associated with aging, lower socioeconomic status, low physical activity and also with reduced fibre, water and magnesium intakes.
Different studies have reported a positive association between the intake of hyper-mineral water containing a high content of bicarbonate, calcium, or magnesium, and the improve of the gastrointestinal transit.
There is evidence that magnesium and sulphate, both individually, have a laxative action.
However, the impact of other minerals is scarce.
It has been described different mechanisms explaining how gut microbiota influence the gastrointestinal transit.
Specifically, in FC patients, it is important to understand the particularities of their gut microbiota and understand whether the intake of hyper-mineral water, a natural source of minerals, can modify positively the gut microbiota.
The aim of the present randomized placebo-controlled pilot trial is to evaluate, for the first time, the effect of the carbonated mineral water consumption in the gastrointestinal transit and in the gut microbiota of subjects with FC.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Inês Mota
- Phone Number: +351 218 803 053
- Email: estudo.agua@nms.unl.pt
Study Contact Backup
- Name: André Rosário, PhD
- Phone Number: +351 218 803 053
Study Locations
-
-
-
Lisbon, Portugal, 1169-056
- Recruiting
- NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA
-
Contact:
- Inês Mota
- Email: estudo.agua@nms.unl.pt
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18 to 70
- Having Functional Constipation diagnosis criteria, according to the Rome IV criteria
- Not using any laxative drug for 3 days before screening visit
- Drinking 1.0 ± 0.5 L of water per day
- Accept and sign the consent
Exclusion Criteria:
- Treatment or disease (current or past) likely to interfere with evaluation of the study parameters
- Taking antibiotics in the 3 months preceding the recruitment visit
- Taking supplements and any food enriched or presented containing bacteria or yeasts likely to have an effect on the gastrointestinal tract, particularly on intestinal transit, digestive comfort, gas production, the occurrence of abdominal pain in the 30 days preceding the recruitment visit (these products will also be banned during the study period)
- Subject having an alcohol consumption of more than 3 glasses of wine a day, or 2 glasses of beer a day, or 1 glass of hard liquor a day
- Subject having a coffee consumption greater than 5 cups per day
- Subject with constipation attributable to an organic or anatomical cause (Hirschsprung's disease, hypothyroidism, mental deficiency, psychiatric illness, neurological abnormalities, history of operation of the colon or anus, colorectal cancer, anemia, etc.)
- Subject with a history of current gastrointestinal pathology or disorder such as duodenal ulcer, chronic colitis, or chronic inflammatory disease of the gastrointestinal tract (Crohn's disease, ulcerative colitis), celiac disease or syndrome irritable bowel
- Subject having a history of operation of the digestive tract
- Subject having undergone surgery in the two months preceding the recruitment visit
- Subject having undergone bariatric surgery
- History of renal disease (renal insufficiency etc.) or cardiovascular disease (cardiac insufficiency...), respiratory disease, neural disease
- Having participated in a weight loss program (with a 5-10% weight) loss in the last 3 months prior to the recruitment visit
- Body mass index > 35 kg/ m2
- Taking supplements of magnesium, vitamins, or other minerals during the study period
- Intake of other carbonated mineral waters beyond the given water, during the study period.
- Pregnancy
- Participation in another clinical trial during the last 30 days prior to the recruitment visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carbonated Natural Mineral Water
750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
|
750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
|
PLACEBO_COMPARATOR: Low Mineral Water
750 mL/day of low mineral water.
|
750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference between the intervention and control group in the change in gastrointestinal transit from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in gastrointestinal transit measured by the percentage of responder subjects defined as a composite score of the two following Rome IV criteria: number of stools ≥ 4 or an increase of 2 stools/week and stools consistency with less than 25% of lumpy to hard stools.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference between the intervention and control group in the change in stool consistency from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in stool consistency measured using Bristol scale.
|
4 weeks
|
Difference between the intervention and control group in the change in constipation symptoms from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in constipation symptoms measured using a validated PAC-SYM questionnaire.
PAC-SYM is a 12-item, self-administered questionnaire used to measure severity of symptoms over the past 2 weeks in patients with constipation.
Cultural adaptation and linguistic validation of the PAC-SYM for Portugal was performed by Mapi Research.
|
4 weeks
|
Difference between the intervention and control group in the change in constipation Quality of Life from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in constipation Quality of Life measured using a validated PAC-QOL questionnaire.
PAC-QOL questionnaire is a 28-item self-administered questionnaire that is being used to measure health-related quality of life (over the past 2 weeks) in patients with chronic constipation.
Cultural adaptation and linguistic validation of the PAC-QOL for Portugal was performed by Mapi Research Trust.
|
4 weeks
|
Difference between the intervention and control group in the change in Perceived Stress Scale from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in constipation Perceived Stress Scale measured using a validated Perceived Stress Scale questionnaire.
A validated Perceived Stress Scale (PSS) self-administered questionnaire with 13-item will be used to measure perceived stress of respondents during the last month (Portuguese version keeps 13 of the 14 original items).
The PSS questionnaire has been demonstrated to have internal consistency, reproducibility, validity, and sensitivity.
Cultural adaptation and linguistic validation of the PSS for Portugal was implemented by Pais-Ribeiro & Marques (2009).
|
4 weeks
|
Difference between the intervention and control group in the change in gut microbiota from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Bacterial DNA will be extracted from fecal samples.
16SRNA gene will be sequenced by next-generation sequencing (NGS).
All the identified bacterial phyla, genus and species will be expressed in percentage.
|
4 weeks
|
Difference between the intervention and control group in the change in short-chain fatty acid profiling from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in short-chain fatty acid profiling evaluated by the faeces concentration of short-chain fatty acids before and after intervention.
|
4 weeks
|
Difference between the intervention and control group in the change in urinary excretion of minerals from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in urinary excretion of minerals evaluated by the K+, Na+, Mg2+ and Ca2+ excretion before and after intervention.
|
4 weeks
|
Difference between the intervention and control group in the change in urinary pH from baseline to the end of follow-up (4 weeks).
Time Frame: 4 weeks
|
Change in urinary pH evaluated by the urine pH before and after intervention.
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 4 weeks
|
Registration of any adverse events.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: André Rosário, PhD, NOVA Medical School | Faculdade de Ciências Médicas da Universidade Nova de Lisboa
- Study Director: Inês Mota, NOVA Medical School | Faculdade de Ciências Médicas da Universidade Nova de Lisboa
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
May 1, 2022
Primary Completion (ANTICIPATED)
November 1, 2022
Study Completion (ANTICIPATED)
December 1, 2022
Study Registration Dates
First Submitted
May 11, 2022
First Submitted That Met QC Criteria
May 11, 2022
First Posted (ACTUAL)
May 16, 2022
Study Record Updates
Last Update Posted (ACTUAL)
May 16, 2022
Last Update Submitted That Met QC Criteria
May 11, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MineralWaterGut
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Constipation
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Huazhong University of Science and TechnologyWuhan Union Hospital, China; Guangzhou University of Traditional Chinese Medicine and other collaboratorsUnknownFunctional Constipation | Functional DiarrheaChina
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
-
Gelesis, Inc.Not yet recruitingConstipation - Functional
-
Wageningen University and ResearchAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); FrieslandCampina... and other collaboratorsRecruitingFunctional ConstipationNetherlands
-
University of AlexandriaCompletedFunctional ConstipationEgypt
-
The First Affiliated Hospital of Xiamen UniversityEnrolling by invitationFunctional ConstipationChina
Clinical Trials on Carbonated Natural Mineral Water
-
Simon Fraser UniversityRecruitingSyncope | Orthostatic Hypotension | Vasovagal SyncopeCanada
-
American Society Of Thermalism And Climatology IncUnknownViolence | Substance Abuse Problem | Homicide | Assault by Handgun Discharge | Sexual Assault by Bodily ForceUnited States
-
George Washington UniversityCompletedObesity | Diabetes
-
DoubleGood ABLund UniversityCompletedType 2 Diabetes Mellitus | Metabolic Syndrome | Postprandial HyperglycemiaSweden
-
My Goodlife SASCompleted
-
Singapore General HospitalUnknown
-
Danone ResearchCompletedRecurrent Urinary Tract InfectionBulgaria
-
National Research Council, SpainCompleted
-
Hiroshima UniversityHita Tenryosui Co., Ltd.Completed
-
National Research Council, SpainVichy Catalán, SpainCompleted